Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) has been given an average recommendation of “Hold” by the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.60.
Several analysts have recently weighed in on DRTS shares. LADENBURG THALM/SH SH boosted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Finally, Piper Sandler boosted their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th.
Get Our Latest Stock Analysis on Alpha Tau Medical
Alpha Tau Medical Stock Down 6.7%
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last announced its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Sell-side analysts expect that Alpha Tau Medical will post -0.67 EPS for the current year.
Insider Buying and Selling
In other Alpha Tau Medical news, CFO Raphi Levy sold 32,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total value of $351,975.00. Following the completion of the sale, the chief financial officer owned 147,680 shares in the company, valued at approximately $1,599,374.40. The trade was a 18.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 112,270 shares of company stock worth $1,270,923 over the last quarter. Insiders own 39.50% of the company’s stock.
Hedge Funds Weigh In On Alpha Tau Medical
A number of institutional investors have recently modified their holdings of DRTS. Renaissance Technologies LLC purchased a new stake in Alpha Tau Medical in the 1st quarter valued at $286,000. Principal Financial Group Inc. purchased a new position in Alpha Tau Medical during the 1st quarter worth $132,000. Millennium Management LLC grew its position in Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after purchasing an additional 70,081 shares during the last quarter. Mariner LLC grew its position in Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after purchasing an additional 1,915 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the period. 2.65% of the stock is owned by institutional investors and hedge funds.
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Read More
- Five stocks we like better than Alpha Tau Medical
- AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
- Silicon Starvation: Amazon Feasts on Legacy GPUs
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
